ReviewBiomedicines2026
Bidirectional Crosstalk Between Vulnerable Coronary Plaque and Coronary Microvascular Dysfunction: A Narrative Review.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary microvascular dysfunction (CMD) is a major contributor to myocardial ischaemia and angina, both in the presence and absence of obstructive coronary artery disease, yet it remains underdiagnosed and therapeutically challenging. The mechanistic links between CMD, myocardial ischaemia, and major adverse cardiovascular events (MACE) are incompletely understood. Emerging mechanistic, imaging, and clinical evidence suggests that CMD and vulnerable plaque (VP) could be connected through shared inflammatory, metabolic, and haemodynamic pathways. This review synthesises data across these domains to propose a bidirectional plaque-microcirculatory crosstalk framework, whereby each process may amplify the other. Evidence indicates that plaque-derived inflammatory mediators and haemodynamic disturbances can impair microvascular function, while CMD-related flow abnormalities may, in turn, accelerate plaque inflammation, progression, and destabilisation. Furthermore, distinct CMD endotypes (e.g., structural or functional) have different underlying pathophysiology and present with different phenotypes. Identifying mediators of coronary-microvascular crosstalk presents an opportunity to refine cardiovascular risk stratification and uncover novel therapeutic targets. Current anti-inflammatory therapies have shown variable effects, and CMD-directed vasomodulatory interventions have produced mixed results, partly due to limited endotype stratification. Emerging approaches, including coronary sinus reducer therapy and precision anti-inflammatory strategies, may offer dual benefits by improving CMD and stabilising vulnerable plaques. This review examines the bidirectional crosstalk hypothesis, aiming to provide an integrative framework linking epicardial atherosclerosis and microvascular pathology and may guide future phenotype-specific mechanistic and interventional studies aimed at reducing residual cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.